August 2022 - PsychedelicNewsWire (PNW)

WednesdayAug 31, 2022 1:33 pm

Researchers Push DEA to Rescind Psychedelic Restriction Plan

In April, the DEA announced its intent to place certain hallucinogens in Schedule I, which would make it harder for researchers to conduct studies investigating the therapeutic potential of those substances. This is in addition to criminalizing said substances. However, after scientists from Emory University and Panacea Plant Sciences challenged this action, the agency decided to withdraw the proposal altogether. In a recently released notice, the agency stated that it would rescind the ban on DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) and would instead publish a new proposed rule. The DEA’s justification for the original ban wasn’t backed by sufficient evidence…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

TuesdayAug 30, 2022 12:36 pm

Psychedelics Company Raises More than $10M in Seed Funding to Advance Ketamine Therapy

Freedom Biosciences is a leading biotechnology platform focused on developing next-generation psychedelic therapies. The company was founded in April 2021 by Dina Burkitbayeva and Dr. John Krystal. Burkitbayeva is also the cofounder of PsyMed Ventures while Krystal is the psychiatry department chair at Yale University. The company has raised $10.5 million in seed financing and focused on advancing a ketamine therapy for the treatment of major depressive disorder. Ketamine is a dissociative drug that is commonly used as an anesthetic, as well as a drug to manage acute pain. Recent studies have found that the drug may also be useful…

MondayAug 29, 2022 12:38 pm

How Psychedelics Startups Are Improving Their Resilience

After decades of prohibition and criminalization, psychedelic policies are finally starting to loosen up amid a significant surge in psychedelics research. The resulting scientific studies into the probable benefits and risks of hallucinogenic drugs have revealed that the substances can indeed be effective against a variety of mental health conditions, especially when combined with psychotherapy. As such, the nascent psychedelic industry has attracted numerous startups that would like to develop novel psychedelic-assisted therapies. The industry is projected to be worth $6.63 billion in 2026, and plenty of companies are keen on taking a slice of these profits for themselves. But…

FridayAug 26, 2022 12:20 pm

DEA Delay Leaves Synthetic Psychedelics in Legal Limbo

Psychedelics are currently experiencing a renaissance that has been characterized by a significant surge in scientific research, public interest and reform efforts. Said to be effective against mental health conditions such as eating disorders, anxiety, depression and post-traumatic stress disorder, psychedelics have been subject to several legislative efforts across the country as activists have tried to get them legalized for medical use. There are a wide variety of psychedelics, including a class of artificial psychedelics that are synthesized in a laboratory rather than extracted from a natural source. In 2021, the U.S. Drug Enforcement Agency (DEA) announced that it was…

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

ThursdayAug 25, 2022 12:12 pm

Study Finds More Than 5.5 Million Adults in the US Use Hallucinogens

Hallucinogens are drugs that alter an individual’s feelings and thoughts as well as the awareness of their surroundings. These drugs are usually classified as either dissociative drugs or classic hallucinogens. Classic hallucinogens include LSD, MDMA, ayahuasca, THC and mescaline while dissociative drugs include PCP (phencyclidine), ketamine and DXM, which is also known as lean. New research has found that the use of hallucinogens in America has significantly risen among adults in the last 20 years. This research is the first to provide formal statistical analyses of trends on the use of hallucinogens in the last two decades. The study was…

WednesdayAug 24, 2022 11:59 am

How Meditation, Psychedelics Can Boost Healing

Psychedelics have seen a surge in popularity amid significantly increased interest in both the mainstream and scientific communities. Initial studies show that these mind-altering drugs have the potential to alleviate mental health conditions such as post-traumatic disorder, anxiety, eating disorders and treatment-resistant depression. The studies revealed that even a single psychedelic trip can have profound long-term effects on a patient’s mental health. As such, researchers across the country have been working to develop psychedelic-assisted therapies that can have positive long-term mental health outcomes. Practitioners in the health and wellness sector have been particularly interested in psychedelics because of their ability…

TuesdayAug 23, 2022 11:56 am

California Senator Sees New Path to Get Psychedelics Decriminalization Bill Approved

The possession and use of psychedelic drugs won’t be allowed anytime soon in the state of California after a psychedelics bill failed to pass. Bill SB 519, which had advanced past the Senate, was passed by two committees and went through a series of amendments in an appropriations committee that removed ketamine from the list of allowed psychedelics and introduced possession limits. Despite that, psychedelic reform advocates say that the legislation was essentially gutted in an Assembly Appropriations Committee meeting last week, with lawmakers introducing provisions such as possession limits that irked many advocates. Before last week’s Appropriations Committee meeting,…

MondayAug 22, 2022 12:41 pm

FT-104: Field Trip’s Latest Psychedelic Drug Candidate

Thanks to increased scientific interest in psychedelics because of their purported mental health benefits, the substances have seen a significant resurgence in mainstream popularity. Reform activists across the country have spent the last couple of years trying to legalize psychedelics amid a slew of studies that have found the drugs to be quite effective at treating conditions such as depression, post-traumatic stress disorder (PTSD) and even eating disorders. This hasn’t been limited to popular psychedelics such as MDMA, ketamine and psilocybin, the main psychoactive agent in magic mushrooms. Activists were recently able to get the Drug Enforcement Administration (DEA) to…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: August 2022